Similar articles

• Inhibition of cardiac guanylate cyclase by doxorubicin and some of its analogs: possible relationship to cardiotoxicity.

  Lehotay DC, Levey BA, Rogerson BJ, Levey GS. Lehotay DC, et al. Cancer Treat Rep. 1982 Feb;66(2):311-6. Cancer Treat Rep. 1982. PMID: 6120040
• Selective inhibition of rat and human cardiac guanylate cyclase in vitro by doxorubicin (adriamycin): possible link to anthracycline cardiotoxicity.

  Levey GS, Levey BA, Ruiz E, Lehotay DC. Levey GS, et al. J Mol Cell Cardiol. 1979 Jun;11(6):591-9. doi: 10.1016/0022-2828(79)90433-4. J Mol Cell Cardiol. 1979. PMID: 37344 No abstract available.
• Inhibition of cardiac guanylate cyclase by doxorubicin and some of its analogs.

  Lehotay DC, Levey BA, Levey GS. Lehotay DC, et al. Biomed Pharmacother. 1983;37(7):312-6. Biomed Pharmacother. 1983. PMID: 6141818
• Adriamycin cardiotoxicity and calcium entry blockers: the need for caution in the combination.

  Rabkin SW, Godin DV. Rabkin SW, et al. Can J Cardiol. 1985 Sep-Oct;1(5):IV-VII. Can J Cardiol. 1985. PMID: 3021301 Review. No abstract available.
• Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls.

  Robert J. Robert J. Cell Biol Toxicol. 2007 Jan;23(1):27-37. doi: 10.1007/s10565-006-0142-9. Epub 2006 Oct 13. Cell Biol Toxicol. 2007. PMID: 17041747 Review.